First results achieved with A(H1N1) wild type strain shows significant time savings of cell-based production over egg-based manufacturing approach confirming its value in pandemic situations.
Novartis is launching a new initiative in a dynamically changing healthcare industry environment that will enhance productivity by streamlining the organization and redesigning the way it operates.
Novartis and the Massachusetts Institute of Technology have launched a long-term research collaboration aimed at transforming the way pharmaceuticals are produced.
US Department of Health and Human Services (HHS) awarded yesterday contracts GlaxoSmithKline, Novartis and Iomai Corp. valued at $132.5 million for developing a vaccine for bird flu.
